8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 5, 2026·SEC
Contineum Therapeutics, Inc. Class A Common Stock(CTNM)Earnings, Financials & Key Ratios
CTNM•NASDAQ
$14.19
Price updated Jun 27, 2026
AboutContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$68M-33.8%
- Net Income-$60M-41.9%
- EPS (Diluted)-2.17-33.1%
- ROE-26.13%+59.8%
CTNM Price & Volume
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
"Contineum Therapeutics remains a pre-revenue biotechnology firm entirely dependent on the successful clinical progression of its PIPE-791 and PIPE-307 assets. The company faces significant financial pressure as R&D expenditures reached $11.6 million in 2026Q1, necessitating careful monitoring of its narrowing cash reserves. Investors should remain cautious regarding the potential for future dilutive financing events given the persistent negative free cash flow and the absence of commercial revenue streams."
Verdict Logic
the rapid depletion of cash reserves to $20.2 million in 2026Q1, coupled with a $16.6 million quarterly free cash flow deficit, suggests an urgent need for external capital that may lead to significant shareholder dilution.
CTNM Growth Metrics
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.04%
Return on Capital
10 Years-32.67%
5 Years-32.67%
3 Years-26.39%
Last Year-28.98%
CTNM Recent Earnings
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.39+29.1%
$0.55
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.49+2.0%
$0.50
Rev
—
$8M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.45+22.4%
$0.58
Rev
—
$5M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.62-10.7%
$0.56
Rev
—
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.39vs $0.55+29.1% | — |
| Q2 2026 | Mar 5, 2026 | $0.49vs $0.50+2.0% | —vs $8M |
| Q4 2025 | Oct 30, 2025 | $0.45vs $0.58+22.4% | —vs $5M |
| Q3 2025 | Aug 5, 2025 | $0.62vs $0.56-10.7% | —vs $8M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.19 | $530.51M | -6.54 | — | — | -26.13% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — |
Compare CTNM vs Peers
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTNM SEC Filings & Documents
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CTNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTNM Frequently Asked Questions
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CTNM profitable?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported a net loss of $58.4M for fiscal year 2025.
Dividend & Returns
What is CTNM's return on equity?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a return on equity (ROE) of -26.1%. Negative ROE indicates the company is unprofitable.
What is Contineum Therapeutics, Inc. Class A Common Stock's free cash flow?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) had negative free cash flow of $57.7M in fiscal year 2025, likely due to heavy capital investments.